Subsequently, it was also analyzed that P53 activation and FUS expression and found that FUS expression were phenomenally higher in P53-activated PRAD patients (38 cases) than in normal controls and P53-inactive PRAD patients (P < 0.001) (Figure 1(c)). This evidence concerns the gene TP53 and prostate adenocarcinoma.